These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 12097284)

  • 21. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
    Fukuda K; Abei M; Ugai H; Seo E; Wakayama M; Murata T; Todoroki T; Tanaka N; Hamada H; Yokoyama KK
    Cancer Res; 2003 Aug; 63(15):4434-40. PubMed ID: 12907616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
    Yu DC; Sakamoto GT; Henderson DR
    Cancer Res; 1999 Apr; 59(7):1498-504. PubMed ID: 10197620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells.
    Chen L; Chen D; Gong M; Na M; Li L; Wu H; Jiang L; Qian Y; Fang G; Xue X
    Cancer Lett; 2009 Nov; 284(2):141-8. PubMed ID: 19447545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector.
    Wang D; Wang Z; Tian J; He X; Chowdhury WH; Zhang X; Li S; Rodriguez R
    Urol Oncol; 2010; 28(2):164-9. PubMed ID: 18440837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.
    Wang L; Zhang Y; Zhao J; Xiao E; Lu J; Fu S; Wang Z
    Tumour Biol; 2014 Nov; 35(11):10879-90. PubMed ID: 25085582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
    Shirakawa T; Hamada K; Zhang Z; Okada H; Tagawa M; Kamidono S; Kawabata M; Gotoh A
    Clin Cancer Res; 2004 Jul; 10(13):4342-8. PubMed ID: 15240520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.
    Geoerger B; Grill J; Opolon P; Morizet J; Aubert G; Terrier-Lacombe MJ; Bressac De-Paillerets B; Barrois M; Feunteun J; Kirn DH; Vassal G
    Cancer Res; 2002 Feb; 62(3):764-72. PubMed ID: 11830531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting gene expression of the mouse uroplakin II promoter to human bladder cells.
    Zhu H; Zhang ZA; Xu C; Huang G; Zeng X; Wei S; Zhang Z; Guo Y
    Urol Res; 2003 Mar; 31(1):17-21. PubMed ID: 12624658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
    Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
    Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
    Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
    Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
    Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
    Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma.
    Zhang ZT; Pak J; Shapiro E; Sun TT; Wu XR
    Cancer Res; 1999 Jul; 59(14):3512-7. PubMed ID: 10416618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
    Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
    Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lentivirus-mediated p21/Waf-1 short hairpin RNA enhances the cytotoxic effects and replicative potential of a bladder cancer-specific oncolytic adenovirus in vitro.
    Shi J; Fu S; Wang L; Tao Y; Rodriguez R; Wang Z
    Anticancer Drugs; 2017 Jan; 28(1):88-96. PubMed ID: 27622605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo.
    Bass C; Cabrera G; Elgavish A; Robert B; Siegal GP; Anderson SC; Maneval DC; Curiel DT
    Cancer Gene Ther; 1995 Jun; 2(2):97-104. PubMed ID: 7621262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer.
    Olsburgh J; Harnden P; Weeks R; Smith B; Joyce A; Hall G; Poulsom R; Selby P; Southgate J
    J Pathol; 2003 Jan; 199(1):41-9. PubMed ID: 12474225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
    Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
    Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.